Ali Bazarbachi
Overview
Explore the profile of Ali Bazarbachi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
316
Citations
4153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Passweg J, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39939433
In 2023, 47,731 HCT (20,485 (42.9%) allogeneic and 27,246 (57.1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were...
2.
Moukalled N, Malard F, Bazarbachi A, Mohty M
Presse Med
. 2024 Dec;
54(1):104261.
PMID: 39662763
Minimal Residual Disease (MRD) in multiple myeloma has emerged as a significant prognostic factor, guiding treatment strategies and enhancing patient outcomes. Despite advancements in therapies such as proteasome inhibitors, immunomodulatory...
3.
Passweg J, Baldomero H, Alexander T, Angelucci E, Averbuch D, Bazarbachi A, et al.
Bone Marrow Transplant
. 2024 Nov;
60(2):227-236.
PMID: 39578528
We looked at treatment rates and center density across countries for patients treated in 2022; 46,143 HCTs (19,011 (41.2%) allogeneic, 27,132 (58.8%) autologous) reported by 689 centers. 4329 patients received...
4.
Schmalter A, Labopin M, Versluis J, Gallego Hernanz M, Eder M, Borne P, et al.
Am J Hematol
. 2024 Nov;
100(1):85-92.
PMID: 39558209
Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease-defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification....
5.
Raj K, Eikema D, Lawless S, Koster L, Kunadt D, Kroger N, et al.
Bone Marrow Transplant
. 2024 Nov;
60(2):220-226.
PMID: 39533014
Therapy-related myeloid neoplasms (t-MN) are a complication of multiple myeloma (MM) treatment. Our retrospective, EBMT registry study included 157 such patients allografted (allo-HCT) between 2006 and 2018. Most patients (130)...
6.
Bekadja M, Niederwiser D, Kharfan-Dabaja M, El Fakih R, Garderet L, Yakoub-Agha I, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):19-27.
PMID: 39375527
Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard...
7.
Larue M, Labopin M, Brissot E, Alaskar A, Aljurf M, Arat M, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):28-31.
PMID: 39375526
This international questionnaire survey aimed to explore the current incidence, diagnostic policies, management, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) among healthcare providers involved in the management of these...
8.
El Hajj H, Hermine O, Bazarbachi A
Leuk Res
. 2024 Oct;
147:107598.
PMID: 39366194
Adult T cell leukemia (ATL) is an aggressive blood malignancy secondary to chronic infection with the human T cell leukemia virus type I (HTLV-1) retrovirus. ATL encompasses four subtypes (acute,...
9.
Bazarbachi A, Avet-Loiseau H, Harousseau J, Bazarbachi A, Mohty M
Cancer Treat Rev
. 2024 Sep;
130:102823.
PMID: 39255732
The t(11;14) translocation is among the most prevalent cytogenetic abnormalities in multiple myeloma (MM), distinguished by its unique features and biology that have been thoroughly explored for decades. What further...
10.
Moukalled N, Abou Dalle I, El Cheikh J, Ye Y, Malarad F, Mohty M, et al.
Curr Opin Oncol
. 2024 Sep;
36(6):583-592.
PMID: 39246181
Purpose Of Review: The past two decades have witnessed an impressive expansion in the treatment landscape of multiple myeloma, leading to significant improvements in progression-free; as well as overall survival....